StockNews.AI

RAD Increases Ownership in Radiopharm Ventures to 87.5%

StockNews.AI • 1 minute

MDACAXASBMRN
High Materiality9/10

Information

SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiophar...

Original source

AI Summary

Radiopharm increased ownership in Radiopharm Ventures from 75% to 87.5%. Betabart has received FDA IND clearance for Phase I trials in 2026. B7H3 is overexpressed in cancer tissues, linked to tumor aggression. Positive results from preclinical candidates boost confidence in future therapies. Radiopharm Ventures aims to develop novel radiopharmaceutical products for cancer.

Sentiment Rationale

The increase in ownership and recognition from the FDA signals strong confidence and value creation potential. Similar past increases in ownership within successful biotech companies often resulted in positive market reactions.

Trading Thesis

The imminent dosing of patients in the Phase I trial may drive short-term investor interest and stock price movement, reminiscent of other companies that saw stock rallies leading up to clinical trial announcements.

Market-Moving

  • Radiopharm increased ownership in Radiopharm Ventures from 75% to 87.5%.
  • Betabart has received FDA IND clearance for Phase I trials in 2026.
  • B7H3 is overexpressed in cancer tissues, linked to tumor aggression.

Key Facts

  • Radiopharm increased ownership in Radiopharm Ventures from 75% to 87.5%.
  • Betabart has received FDA IND clearance for Phase I trials in 2026.
  • B7H3 is overexpressed in cancer tissues, linked to tumor aggression.
  • Positive results from preclinical candidates boost confidence in future therapies.
  • Radiopharm Ventures aims to develop novel radiopharmaceutical products for cancer.

Companies Mentioned

  • MDAC (MDAC)
  • AXAS (AXAS)
  • BMRN (BMRN)

Corporate Developments

The article indicates significant advancements and FDA clearance, representing pivotal moments for RADX. With a promising pipeline and increased ownership, investor confidence is likely to strengthen, impacting stock performance positively.

Radiopharm Increases Stake in Radiopharm Ventures to 87.5%

SYDNEY, January 12, 2026 — Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX), a clinical-stage biopharmaceutical company specializing in innovative oncology radiopharmaceuticals, has announced a significant increase in its ownership of Radiopharm Ventures, LLC from 75% to 87.5%. This strategic move reflects the joint venture's ongoing advancements in its cancer therapeutic pipeline, particularly with its leading candidate targeting B7H3.

Details on Radiopharm Ventures

Radiopharm Ventures, formed in collaboration with The University of Texas MD Anderson Cancer Center (MDACC) in 2022, focuses on developing novel radiopharmaceutical products for the treatment of cancer. The company’s leading candidate, Betabart, a monoclonal antibody, has successfully received FDA Investigational New Drug (IND) clearance for a Phase I therapeutic trial. This trial, which aims to treat multiple solid tumors, is expected to dose its first patient in Q1 2026.

  • Ownership increased from 75% to 87.5%.
  • Betabart targets the B7H3 immune checkpoint protein.
  • First patient in Phase I trial anticipated to be dosed in Q1 2026.
  • Positive progress reported for two additional preclinical assets.

Significance of B7H3 in Cancer Treatment

B7H3 is rarely found in healthy cells but is overexpressed in various cancers, correlating with larger tumor sizes and increased lymphatic invasion. This makes it a promising target for cancer therapies. Riccardo Canevari, CEO & Managing Director of Radiopharm, expressed optimism about the venture's progress, stating, “Now is an exciting time to increase our ownership in the joint venture, as we will soon have first-in-human results of Betabart from our Phase I study.”

Future Prospects and Clinical Development

As part of its commitment to innovation in cancer treatment, Radiopharm Ventures is on track to select final candidates for two additional preclinical assets, focusing on solid tumor applications. The collaboration between Radiopharm and MDACC capitalizes on mutual expertise in antigen discovery, molecular imaging, and targeted therapies, marking a significant step forward in oncology.

Radiopharm continues to establish its presence in the biopharmaceutical landscape, with a clinical development program that includes one Phase 2 trial and four Phase 1 trials targeting various solid tumor cancers, including lung, breast, and brain metastases.

About Radiopharm Theranostics

Radiopharm Theranostics is recognized for its innovative approach to developing radiopharmaceutical products aimed at high unmet medical needs. With a diverse pipeline that encompasses peptides, small molecules, and monoclonal antibodies, Radiopharm is committed to improving cancer diagnosis and therapy. The company trades on both the Australian Securities Exchange (ASX: RAD) and the Nasdaq (RADX).

Related News